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Abstract
Telomerase activity is primarily determined by transcriptional regulation of the catalytic subunit, human telomerase
reverse transcriptase (hTERT). Several mRNA splice variants for hTERT have been identified, but it is not clear if
telomerase activity is determined by the absolute or relative levels of full-length (functional) and variant hTERT
transcripts. We have developed an SYBR green–based reverse transcription–quantitative polymerase chain re-
action assay for the enumeration of the four common hTERT mRNA variants and correlated these with telomerase
activity and telomere length in 24 human melanoma cell lines. All except five of the lines expressed four hTERT
transcripts, with an overall significant level of co-occurrence between absolute mRNA levels of full-length α+/β+
hTERT and the three splice variants α−/β+, α+/β−, and α−/β−. On average, α+/β+made up the majority (48.1%)
of transcripts, followed by α+/β− (44.6%), α−/β− (4.4%), and α−/β+ (2.9%). Telomerase activity ranged from 1 to
247 relative telomerase activity and correlated most strongly with the absolute amount of α+/β+ (R = 0.791, P =
.000004) and the relative amount of α+/β− (R = −0.465, P = .022). This study shows that telomerase activity in
melanoma cells is best determined by the absolute expression of full-length hTERT mRNA and indicates a role for
the hTERT β deletion variant in the negative regulation of enzyme activity.
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Introduction
Telomerase is a ribonucleoprotein complex that maintains chromo-
some length by synthesizing and adding repetitive (TTAGGG)n
DNA sequences to the ends of telomeres [1]. Its absence from most
normal somatic cells is believed to contribute to eventual senescence
and limited cellular life span [2], whereas its reactivation in immor-
talized cells has been associated with the unlimited growth potential
required for malignancy [3–5]. In particular, progression of mela-
noma is known to be accompanied by a steady increase in telomerase
activity during the transformation of isolated naevi to metastatic dis-
ease [6,7], with virtually all melanoma cell lines exhibiting some de-
gree of telomerase activity [6]. These discriminating properties have
made telomerase an attractive target for cancer therapy [8], and there
has been much emphasis on methods for detecting and determining
the regulatory mechanisms of this important enzyme.
Telomerase is made up of two essential components: a constitu-
tively expressed human telomerase RNA (hTR), which acts as a tran-
scription template [9,10], and a catalytic human telomerase reverse
transcriptase (hTERT), whose expression controls enzymatic activity
Abbreviations: hTERT, human telomerase reverse transcriptase; RTA, relative telome-
rase activity; hTR, human telomerase RNA
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[11,12]. The transcriptional and posttranscriptional regulation of
hTERT is complex and remains to be fully elucidated. Studies in
human development have revealed the presence of multiple hTERT
RNA transcripts occurring in patterns that are both tissue-specific
and gestational stage–dependent [13]. Such nonrandom alternative
splicing is a common method of genetic regulation in eukaryotes
[14], and to date, 10 different splice variants of hTERT have been
identified [13,15–17]. The most widely studied variants involve splic-
ing at two main sites: the α splice site, which produces a 36-bp in-
frame deletion within the conserved reverse transcript motif A; and
the β site, which results in a 183-bp deletion and non–sense mutation
that truncates the protein, effectively deleting the remaining three re-
verse transcriptase motifs [13,18]. Splicing at either site can occur
independently or in combination to produce three variants from the
full-length α+/β+: α−/β+, α+/β−, and α−/β−, which have been shown
to occur at approximate proportions of 5%, 1%, 80% to 90%, and
5% to 15%, respectively, within various cancer cell lines [19]. To date,
only the α−/β+ variant has been shown to exhibit any regulatory func-
tion, acting as a dominant-negative inhibitor of telomerase activity
when overexpressed in either normal or tumor cells [20,21]. It is un-
clear whether the ratio of full length to spliced hTERT is important in
determining telomerase activity [22], because some studies have shown
that the absolute expression of hTERT is well correlated with telome-
rase activity [23–27], and still others have found no correlation with
either relative or absolute amounts of variant transcripts [28]. The
regulatory functions of various hTERT transcripts may well be cell
type–specific; however, the many different methods used to quantify
hTERTmRNA have made it difficult to interpret these findings.
Most reverse transcription–polymerase chain reaction (RT-PCR)–
based assays for hTERT variants use primers that flank the α and
β subunits and thus amplify all transcripts in one reaction (Figure 1).
The products are then scanned by densitometry to give the relative
distribution of hTERT variants in each sample [19,29,30], the re-
sults of which are largely biased by the competitive nature of PCR.
A few techniques have been developed using dual-labeled probe tech-
nology on a real-time PCR platform [31–35]; however, most of these
assays use primers designed to the region downstream from the α
and β subunits and, therefore, do not discriminate between the de-
letion variants [31–33]. A commercially available Light Cycler kit
(TeloTAGGGG hTERT Quantification Kit; Roche Diagnostics,
Basel, Switzerland) has proven popular, but the exact primer se-
quences are not revealed, thus it is not clear which transcripts are
measured. Therefore, results from these types of studies need to be
interpreted with caution.
The aim of the present study was to establish whether absolute
or relative levels of hTERT variant transcripts determine telomerase
activity. We developed an SYBR green–based real-time PCR assay
as a more affordable option to labeled probes, with the further ad-
vantage of enabling melt curves to confirm the presence of specific
transcripts. The assay was then used to determine the absolute and
relative hTERT variant expression in a series of melanoma cell lines.
In doing so, we have revealed the importance of overall levels of full-
length hTERT mRNA in determining telomerase expression, and a
possible role for the relative amount of β deletion variant in the
regulation of telomerase activity.
Materials and Methods
Cell Lines
A total of 24 human melanoma cell lines were used for this study.
ME4405 was a kind gift from Dr. Parmiani (Milan, Italy). MM200
was supplied by Dr. Parsons (Queensland Institute of Medical Re-
search, Brisbane, Australia), and IGR3 was provided by Dr. Hope
(Institute of Medical and Veterinary Science, Adelaide, Australia).
Clones of the latter two lines along with the remaining lines, which
were developed from primary melanoma tissue biopsies after re-
ceiving informed patient consent, were kindly provided by the New-
castle Melanoma Unit, Calvary Mater Newcastle. HL60 was
obtained from the American Type Culture Collection (Manassas,
VA) for use as a control. All melanoma cells were cultured in DMEM
(JRH Biosciences, Australia), and HL60 was maintained in RPMI
1640 (JRH Biosciences), supplemented with 10% fetal bovine serum
at 37°C and 5% CO2.
Telomerase Activity
Telomerase activity was determined using the Telo TAGGG Telo-
merase PCR ELISAplus kit (Roche, Mannheim, Germany), which is
based on the Telomeric Repeat Amplification Protocol assay with a
nonradioactive ELISA detection. The procedure was performed on
3 ng of total cell protein in accordance with the manufacturer’s instruc-
tions and results normalized to the cell line MM200 C3E8. All assays
were performed singly and repeated on three separate occasions.
Measurement of Mean Telomere Length
The mean telomere length of each cell line was determined using
Southern blot techniques as previously reported [36,37]. Briefly, ge-
nomic DNA was isolated and digested with restriction enzymes, RsaI
and MspI (Amersham Pharmacia Biotech, Uppsala, Sweden), electro-
phoresed through a 0.6% agarose gel and transferred to Hybond N+
membrane (Amersham Pharmacia Biotech). A fluorescein-labeled
oligonucleotide probe (CCCTAA)3 was hybridized to the mem-
brane and detected using enhanced chemiluminescent detection
(Amersham Pharmacia Biotech). Kodak Digital Science documenta-
tion software was used to determine the net intensity at 1-kbp in-
tervals along the length of the telomere smear. The mean telomere
Figure 1. hTERT mRNA α and β deletion variants. Relevant hTERT
exons are numbered and corresponding location of α and β se-
quences are illustrated by shaded boxes. Deleted sequences are des-
ignated by dashed lines. Locations of PCR primers are indicated by
arrows and labeled according to the notation used in Tables 1 and 2.
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length was calculated as: Σ(MWi × NIi)/Σ(NIi), where MWi =
molecular weight (kbp) at interval i and NIi = net intensity (pixels)
at interval i [38]. Assessment of the accuracy of the methodology
showed a mean ± SE within-day variation of telomere length of 6 ±
1% and between-day variation of 9 ± 2% [36]. For each sample, the
average of three mean telomere lengths calculated from three separate
blots was used for statistical analysis.
Polymerase Chain Reaction
The full-length hTERT and the three splice variants were ampli-
fied from the HL60 cell line by PCR using previously reported pri-
mers and methods [16,39]. HL60 was used for optimization because
it has been shown to express all four hTERT variants [29]. Products
were resolved by agarose gel electrophoresis and identified based on
size (Table 1). Bands were extracted from the gel and were purified
using the Wizard SV Gel and PCR Clean-Up System (Promega,
Madison, WI). These fragments were used to establish specificity
and sensitivity of the qPCR method.
Establishment of the qPCR Assay
Purified PCR products of each variant were used to optimize the
qPCR cycling conditions. Specific primers were designed to the bound-
ary spanning regions of the α and β subunits of hTERT, because this
has been shown to be an effective way to detect splice variants without
the use of probes [40]. These primers were combined with previously
reported primers designed to hybridize to the α (hTERT 2172 [39])
and β subunits (variation of hTERT 2350 [39]) and thus only amplify
variants containing these sequences (Table 2). Standard curves were
generated, and the minimal detection limit was determined to be
one copy per reaction. The specificity of the assay was confirmed by
testing each primer pair against the purified PCR products for all vari-
ants, and in each case, the primers amplified only the splice variant to
which they had been designed, with minimal cross-reactivity.
Reverse Transcription–Quantitative Polymerase
Chain Reaction
Lysates prepared for telomerase activity analysis (previously men-
tioned) were pooled for each cell line and RNA extracted using the
Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA) and quantified
using the RiboGreen RNA Quantification Kit (Molecular Probes,
Eugene, OR) according to the manufacturer’s instructions. Reverse
transcription reactions were standardized to the lowest RNA con-
centration, so that equivalent amounts of RNA (112 ng) from each
cell line were synthesized into cDNA using Superscript III first-
strand cDNA synthesis kit (Invitrogen, Carlsbad, CA). The cDNA
equivalent of 5.6 ng of RNA was then amplified by qPCR in
20-μl reactions using Platinum SYBR Green qPCR Supermix-UDG
(Invitrogen) with 10 μmol of each appropriate primer. Reactions were
run on a Rotor-Gene 3000 (Corbett Life Science, Sydney, Australia)
using a four-step cycling program that consisted of the following: 50°C
for 2 minutes, 95°C for 2 minutes followed by 60 cycles of 95°C for
10 seconds, 53°C or 58°C for 15 seconds, 72°C for 20 seconds, and
data acquisition on the FAM/SYBR channel at 80°C for 10 seconds.
This final acquisition was set to eliminate background fluorescence
generated below this temperature. For GAPDH, a two-step cycling
program was used: 50°C for 2 minutes, 95°C for 2 minutes followed
by 60 cycles of 95°C for 10 seconds, and 60°C for 1 minute with data
acquisition on the FAM/SYBR channel. A melt curve (57-95°C) was
generated at the end of each run to verify specificity.
Data Analysis
Each reaction was performed in duplicate on three separate occa-
sions. Raw fluorescence values were exported and analyzed by Data
Analysis for Real-Time PCR, a freely available excel file containing
an algorithm that calculates the amplification efficiency of each sam-
ple from its amplification profile [41]. This has been validated and
found to give comparable results to other methods of quantitation
without the need for standard curves [41]. We used the average am-
plification efficiency for our calculations, because this has been
shown to give the most accurate results [42]. Outliers were excluded
and the threshold was set based on the mean midpoint (M ) of the
transformed signal range. Expression values (in arbitrary fluorescence
units) were obtained for each hTERT transcript and normalized by
dividing them by individual expression values for GAPDH to pro-
duce R0. The mean of three experiments was determined for each
transcript and expressed as a percentage of the reference cell line,
MM200 C3E8 (absolute expression) or as a percentage of the total
number of hTERT transcripts for each cell line (relative expression).
Spearman’s rank and Pearson’s correlation coefficients were calculated
to assess linear relationships among telomere length, telomerase ac-
tivity, and hTERTmRNA expression. P values < .05 were considered
statistically significant.
Results
The results are summarized in Table 3. Mean telomere length of
the cell lines ranged from 2.19 to 7.37 kbp, with an overall average of
3.97 kbp. Telomerase activity was detected in all cells and expressed
as a percentage of the MM200 C3E8 reference cell line that was
arbitrarily set as 100. Relative telomerase activity (RTA) varied widely
(1-247 RTA), with a mean of 112. Similarly, the absolute expres-
sion of hTERT mRNA transcripts was highly variable. When the
Table 1. Primers and Expected PCR Products for Amplification of hTERT Splice Variants.
Forward Primer Reverse Primer Annealing Temperature (°C) Possible Amplicons (bp)
2164 2620 50−65 (gradient) α+/β+ = 457
α−/β+ = 421
α+/β− = 275
α−/β− = 239
α+ β+ 53 α+/β+ = 202
α− β+ 53 α−/β+ = 172
α+ β− 53 α+/β− = 189
α− β− 58 α−/β− = 159
Table 2. Primers Used for hTERT and GAPDH Amplification.
Primer Orientation Sequence Reference
2164 Sense gcctgagctgtactttgtcaa Krams et al. [39]
2620 Antisense cgcaaacagcttgttctccatgtc Krams et al. [39]
α+ Sense tgtactttgtcaaggtggatgtg Krams et al. [39]
α− Sense ctgagctgtactttgtcaaggac Lincz et al. (this study)
β+ Antisense gtacggctggaggtctgtcaa Variation of [39]
β− Antisense ggcactggacgtaggacgtgg Lincz et al. (this study)
GAPDHA.69 f Sense ctctctgctcctcctgttcgac Carraro et al. [54]
GAPDHA.69 r Antisense tgagcgatgtggctcggct Carraro et al. [54]
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transcripts were expressed as a percentage of the total amount of
hTERT mRNA in each cell line, on average, the full-length α+/β+
made up the majority (48.1%) of transcripts, followed closely by
the α+/β− variant (44.6%). The α−/β− and dominant-negative
α−/β+ variants made up the smallest proportion of transcripts (4.4%
and 2.9%, respectively). The average ratio of full-length transcript
to spliced transcripts was 1.11 (0.04-2.26).
Individually, the full-length hTERT α+/β+ transcript and its α+/
β− variant were detected in all cell lines (Figure 2). Only six cell lines
did not express all of the variants; of these, three did not express
either of the α deletion variants α−/β+ and α−/β−, two lacked only
the α−/β+ transcript, whereas only one failed to express the double-
deletion variant α−/β−.
There was high disparity in the relative proportions of hTERT
mRNA variants among different cell lines (Figure 3). The full-length
transcript was predominantly expressed in most cell lines, whereas
the α+/β− was the main transcript in six lines.
Absolute Expression of the Full-length hTERT Transcript
Is the Best Predictor of Telomerase Activity
The absolute level of each individual hTERT variant was positively
correlated with telomerase activity, with the full-length message
showing the strongest association (R = 0.791, P = .000004; Table 4).
The relative amount of full-length hTERT was also positively cor-
related with telomerase activity, although this was not statistically
significant (R = 0.403, P = .051), whereas the ratio of full-length
hTERT to variant hTERTwas significantly correlated with telome-
rase activity (R = 0.414, P = .044). The relative expression of α+/β−
was negatively correlated with telomerase activity (R = −0.465, P =
.022), whereas there was no significant correlation between telome-
rase activity and relative expression of either of the α deletion variants
(α−/β+, α−/β−).
A High Level of Co-occurrence Exists between hTERT Variants
Despite some cell lines completely lacking expression of particular
variants, there was an overall significant level of co-occurrence be-
tween absolute mRNA levels of the full length hTERT α+/β+ tran-
script and the three splice variants α−/β+ (R = 0.731), α+/β− (R =
0.559), and α−/β− (R = 0.825). Between variants, there was correla-
tion between absolute expression of all hTERT transcripts except
for α−/β+ and α+/β−. When expressed as relative proportions of
hTERT, the amount of α+/β− variant was significantly inversely re-
lated to that of all other transcripts.
Figure 2. RTA and absolute expression of hTERT mRNA transcripts in melanoma cell lines. Levels of RTA and each variant mRNA are
expressed as a percentage of the reference cell line, MM200 C3E8, arbitrarily designated as 100%, and error bars indicate SDs between
three separate experiments.
Table 3. Summary of Results for 24 Melanoma Cell Lines.
Analysis Mean Range
Telomere length (kbp)* 3.97 2.19−7.37
RTA (% of reference cell line) 112 1−247
Absolute hTERT transcript mRNA
(% of reference cell line)
α+/β+ 116 3−430
R0 6.1 × 10
−4 1.6 × 10−5 to 2.2 × 10−3
α−/β+ 115 0−520
R0 4.0 × 10
−5 0.0 to 1.9 × 10−4
α+/β− 96 15−247
R0 4.3 × 10
−4 7.3 × 10−5 to 1.6 × 10−3
α−/β− 60 0−271
R0 7.7 × 10
−5 0.0 to 7.9 × 10−4
Relative hTERT transcript mRNA
(% of all transcripts)
α+/β+ 48.1 3.94−69.3
α−/β+ 2.9 0.0−8.2
α+/β− 44.6 21.9−96.1
α−/β− 4.4 0.0−21.8
Ratio α+/β+:α−/β+, α+/β−, α−/β− 1.11 0.04−2.26
*n = 22.
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Telomere Length Was Not Correlated to Telomerase Activity
Telomere length was not correlated to telomerase activity (R =
−0.233, P = .297) or to absolute or relative expression of any of
the individual hTERT transcripts.
Discussion
The only comprehensive method of hTERT splice variant quantifi-
cation to emerge so far has been a technique developed by Ohyashiki
et al. [35], which uses TaqMan primer/probe sets to determine both
absolute and relative transcript numbers for each of the four main
hTERT variants. A similar approach by Mavrogiannou et al. [34] also
seems to be highly specific for each variant but perhaps not as quan-
titatively reliable because it does not use a reference gene. Ours is the
first report of an SYBR green–based assay that can distinguish between
the four hTERT variant transcripts, providing a more economical op-
tion for such studies.
Unlike results reported for other cell types, the hTERT α+/β+ vari-
ant accounted for the largest fraction of hTERTmessage in this series
of melanoma cells [19,34]. Our data confirms similar results from the
only other investigation of these variants in a series of 52 melanoma
lesions, which also found that expression of the full-length transcript
was generally equal or slightly higher than the spliced variants, with a
prevalence toward expression of the β deletion variant [22]. Taken to-
gether, these results suggest that the relative proportions of variants in
melanoma cells do not follow the pattern described previously for
other immortalized human cells, including mammary, prostate, renal,
and non–small lung carcinoma cell lines [19]. In particular, we found
higher-than-expected proportions of the full-lengthα+/β+, similar to a
recent report on 6 cell lines and 28 non–small cell lung cancer tissue
Figure 3. Relative expression of hTERT mRNA transcripts in melanoma cell lines. Levels of each variant mRNA are expressed as a
percentage of the total four hTERT transcripts per cell line.
Table 4. Correlations with Absolute and Relative Expression of hTERT Variants.
Telomere Length RTA Absolute
α+/β+ α−/β+ α+/β−
Absolute α+/β+ −0.266 (0.231) 0.791 (0.000)
α−/β+ −0.231 (0.299) 0.603 (0.002) 0.731 (0.000)
α+/β− −0.276 (0.214 ) 0.535 (0.007 ) 0.559 (0.004 ) 0.309 (0.141)
α−/β− −0.257 (0.249) 0.614 (0.001) 0.825 (0.000) 0.749 (0.000) 0.547 (0.006 )
Relative
α+/β+ α−/β+ α+/β−
Relative α+/β+ −0.059 (0.793) 0.403 (0.051)
α−/β+ −0.247 (0.268) 0.371 (0.074 ) 0.389 (0.061)
α+/β− 0.143 (0.526 ) −0.465 (0.022) −0.810 (0.000) −0.479 (0.018)
α−/β− −0.232 (0.298) 0.320 (0.127 ) 0.218 (0.305) 0.411 (0.046 ) −0.632 (0.001)
Ratio α+/β+:
α−/β+,
0.047 (0.837 ) 0.414 (0.044 )
α+/β−,
α−/β−
RTA −0.233 (0.297 )
Numbers given are correlation coefficients with associated P values italicized in parenthesis. Statistically significant values are highlighted in bold.
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samples, which found that the α+/β+ made up approximately 50% of
the total transcripts in these cells [34]. These authors also used a quan-
titative real-time PCR analysis that was specific for each variant and
attributed their findings to this more sensitive approach. Thus, it is
not clear if our findings are unique to melanoma cells or simply due
to the different methods used in individual studies.
We found a strong level of co-expression of all three deletion vari-
ants with the full-length transcript, suggesting that up-regulation of
hTERT transcription affects all variants to a similar extent. This phe-
nomenon has also been reported for other cell types, where copy
numbers of full-length hTERT mRNA correlated with all but the
α deletion variant in acute leukemia cells [35] and specifically with
the β deletion variant in cirrhotic liver [25] and melanoma lesions
[22]. Chromosomal imbalances are common in melanoma, and in
particular, the sequences on 5p15.33, which harbor the gene for
hTERT, have been found to be overrepresented in 33% of cases
[43]. This could result in dysregulation of the gene and may account
for the widespread overexpression of all variants. The present study
shows that it is this absolute increase in transcription of hTERT
mRNA that is most important for determining telomerase activity.
Since the discovery that the α deletion variant has dominant-
negative regulatory influences on telomerase [20,21], some studies
have focused on this variant [44]. Only one has specifically addressed
the β deletion variant and found that overexpression does not cause
down-regulation of telomerase activity in immortalized lung fibro-
blasts, prostate carcinoma, or non–small cell lung cancer cell lines
[20]. It is plausible that telomerase regulation by its splice variants
is cell type–specific, as suggested by the precise patterns of splicing
that occur in particular cell types during development [13]. It is
conceivable that these same patterns become reactivated during tu-
morigenesis and, if so, could have profound implications for the de-
velopment of therapeutic telomerase inhibitors.
In the present study, telomere length was not related to telomerase
activity or hTERT gene expression, suggesting that the maintenance
of chromosome length may not be the primary function of telomerase
in these neoplastic cells. This theory is supported by studies showing
that inhibition of telomerase can induce apoptosis of cancer cells in a
manner that is independent of both p53 and telomere shortening [45–
47]. Furthermore, therapeutic induction of differentiation in some
cancer cells is accompanied by a reduction in telomerase activity
[48–51], and recent gene expression profiling has revealed that this
is more likely to be a causative rather than consequential factor of cell
maturation [52]. These alternative roles for telomerase may be regu-
lated through the splicing of hTERT, and further investigation into
thesemechanisms will require the use of sensitive quantitationmethods.
Finally, it is becoming clear that alternative splicing of pre-mRNA
is a common process, affecting at least 74% of human genes and
effectively increasing the coding potential of the genome [53]. Mis-
splicing of cellular genes often occurs in cancer, and deciphering
the regulatory mechanisms governing splice site selection is a rapidly
emerging area of research [53]. Cells such as the melanoma lines
described herein should provide valuable tools to further this field
of knowledge.
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